ProBioGen Signed Agreement on Testing of Neuronal Cell Lines with Serono

10-Apr-2006

ProBioGen AG announced that Serono S.A., Switzerland has signed an agreement to evaluate ProBioGen's novel human neuronal cell line for the production of recombinant proteins.

Under the terms of the Agreement, Serono will explore the feasibility of using the proprietary neuronal cell line of ProBioGen as a host for the production of recombinant proteins. Financial details are not disclosed.

"Our human neuronal cell lines not only have the advantage of producing proteins with human glycosylation patterns, but they also have been developed with a fully documented history, a very important prerequisite for smooth approval of products derived from a cell line," said Michael Schlenk, CEO of ProBioGen AG. "In addition, they have a very high productivity, so we think we have created cell lines that can produce human biopharmaceuticals very cost effectively and with a very high safety profile. We are very glad that we won Serono as the first partner to explore the huge potential of these cell lines as Serono has a lot of experience in developing recombinant proteins."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world biopharmaceutical manufacturing

Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.

20+ products
15+ brochures
View topic world

Topic world biopharmaceutical manufacturing

Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.

20+ products
15+ brochures